You are viewing the site in preview mode
Skip to main content
|
Description
|
Parameter
|
Log Odds Ratio (95% Interval Estimate)
|
|---|
| | |
BPSA
|
PSA
|
|---|
|
Beta blocker
|
β
|
-0.21 (-0.37, -0.05)
|
-0.31 (-0.46, -0.15)
|
|
Demographics
| | | |
|
Female Sex
|
γ
1
|
0.17 (0.06, 0.29)
|
0.12 (-0.01, 0.25)
|
|
Age
| | | |
|
< 65 (reference)
|
.
|
0.00
|
0.00
|
|
65 - 74
|
γ
2
|
-0.19 (-0.32, -0.04)
|
-0.09 (-0.3, 0.12)
|
|
75 - 84
|
γ
3
|
-0.40 (-0.56, -0.24)
|
-0.21 (-0.41, 0.00)
|
|
> 85
|
γ
4
|
-0.71 (-0.94, -0.46)
|
-0.37 (-0.59, -0.14)
|
|
Comorbid conditions
| | | |
|
Cerebrovascular dis.
|
γ
5
|
-0.11 (-0.67, 0.44)
|
0.25 (-0.46, 0.96)
|
|
COPD
|
γ
6
|
-0.32 (-0.60, -0.06)
|
-0.89 (-1.30, -0.49)
|
|
Hyponatremia
|
γ
7
|
-0.02 (-0.26, 0.21)
|
0.03 (-0.33, 0.39)
|
|
Metastatic disorder
|
γ
8
|
-1.42 (-2.33, -0.56)
|
-0.40 (-1.37, 0.57)
|
|
Renal disease
|
γ
9
|
-0.17 (-0.32, 0.01)
|
0.38 (0.15, 0.62)
|
|
Ventricular arrhythmia
|
γ
10
|
-0.12 (-0.63, 0.44)
|
0.12 (-0.62, 0.86)
|
|
Liver disease
|
γ
11
|
-0.52 (-1.03, -0.08)
|
-1.11 (-2.04, -0.19)
|
|
Malignancy
|
γ
12
|
-0.78 (-1.19, -0.34)
|
-0.06 (-0.57, 0.45)
|
|
Shock
|
γ
13
|
-0.06 (-0.56, 0.39)
|
-0.12 (-0.83, 0.58)
|
|
Hospitalization
| | | |
|
Transferred
|
γ
14
|
-0.41 (-0.58, -0.25)
|
-0.01 (-0.22, 0.20)
|
|
Stay (10 day intvs.)
|
γ
15
|
-0.13 (-0.18, -0.09)
|
-0.05 (-0.11, 0.01)
|
|
Heart failure medications
| | | |
|
Digoxin
|
γ
16
|
-0.02 (-0.11, 0.07)
|
0.00 (-0.14, 0.13)
|
|
Diuretic
|
γ
17
|
0.28 (0.09, 0.48)
|
0.72 (0.54, 0.90)
|
|
CCB
|
γ
18
|
0.22 (0.08, 0.35)
|
0.27 (0.10, 0.44)
|
|
ACE inhibitor
|
γ
19
|
0.29 (0.11, 0.45)
|
0.61 (0.47, 0.76)
|
|
ARB
|
γ
20
|
0.18 (-0.06, 0.46)
|
0.53 (0.19, 0.87)
|
|
Statin
|
γ
21
|
0.91 (0.65, 1.24)
|
0.94 (0.76, 1.12)
|
